Search research articles
Contact Us
Filters
Showing results (121-130 of 136) with videos related to
Page
of 14
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2008
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy
Stephen Johnston, Maureen Trudeau, Bella Kaufman, et al.
The Lancet. Oncology
|
February 11, 2024
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial
Carlo Palmieri, Hannah Linden, Stephen N Birrell, et al.
Nature Communications
|
May 14, 2016
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M Spoerke, Steven Gendreau, Kimberly Walter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2021
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>-</sup> Breast Cancer
Mitch Dowsett, Lucy Kilburn, Mothaffar F Rimawi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2005
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
Stephen Chan, Max E Scheulen, Stephen Johnston, et al.
NPJ Digital Medicine
|
May 1, 2020
Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform
Sanket S Dhruva, Joseph S Ross, Joseph G Akar, et al.
Breast Cancer Research and Treatment
|
May 14, 2024
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study
Matilde Corianò, Chiara Tommasi, Anh Thi Lan Dinh, et al.
JAMA Oncology
|
September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial
George W Sledge, Masakazu Toi, Patrick Neven, et al.
Breast Cancer Research and Treatment
|
January 19, 2019
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
Nicolò Matteo Luca Battisti, Belinda Kingston, Judy King, et al.
Neuroimage
|
October 1, 2015
Meta-analysis of real-time fMRI neurofeedback studies using individual participant data: How is brain regulation mediated?
Kirsten Emmert, Rotem Kopel, James Sulzer, et al.
Page
of 14
Search research articles
Search
Showing results (121-130 of 136) with videos related to
Sort By:
Page
of 14
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 24, 2008
Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy
Stephen Johnston, Maureen Trudeau, Bella Kaufman, et al.
The Lancet. Oncology
|
February 11, 2024
Activity and safety of enobosarm, a novel, oral, selective androgen receptor modulator, in androgen receptor-positive, oestrogen receptor-positive, and HER2-negative advanced breast cancer (Study G200802): a randomised, open-label, multicentre, multinational, parallel design, phase 2 trial
Carlo Palmieri, Hannah Linden, Stephen N Birrell, et al.
Nature Communications
|
May 14, 2016
Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant
Jill M Spoerke, Steven Gendreau, Kimberly Walter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 14, 2021
Biomarkers of Response and Resistance to Palbociclib Plus Letrozole in Patients With ER<sup>+</sup>/HER2<sup>-</sup> Breast Cancer
Mitch Dowsett, Lucy Kilburn, Mothaffar F Rimawi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 16, 2005
Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer
Stephen Chan, Max E Scheulen, Stephen Johnston, et al.
NPJ Digital Medicine
|
May 1, 2020
Aggregating multiple real-world data sources using a patient-centered health-data-sharing platform
Sanket S Dhruva, Joseph S Ross, Joseph G Akar, et al.
Breast Cancer Research and Treatment
|
May 14, 2024
The emerging predictive and prognostic role of HER2 in HER2-negative early breast cancer: a retrospective study
Matilde Corianò, Chiara Tommasi, Anh Thi Lan Dinh, et al.
JAMA Oncology
|
September 30, 2019
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy-MONARCH 2: A Randomized Clinical Trial
George W Sledge, Masakazu Toi, Patrick Neven, et al.
Breast Cancer Research and Treatment
|
January 19, 2019
Palbociclib and endocrine therapy in heavily pretreated hormone receptor-positive HER2-negative advanced breast cancer: the UK Compassionate Access Programme experience
Nicolò Matteo Luca Battisti, Belinda Kingston, Judy King, et al.
Neuroimage
|
October 1, 2015
Meta-analysis of real-time fMRI neurofeedback studies using individual participant data: How is brain regulation mediated?
Kirsten Emmert, Rotem Kopel, James Sulzer, et al.
Page
of 14